Digitalis Ventures invests in solutions to unmet needs in health.
Our deep technical, financial, and domain expertise combine to help creatively finance, build, and scale enduring enterprises.
We provide venture capital to early-stage companies across life sciences, health technologies & services, and animal health with the goal of supporting our portfolio companies throughout their development.
The expertise of our multidisciplinary team combines with the expansive network of entrepreneurs, technical experts, research institutions, and financial partners with whom we have worked over the years to allow us to forge deep and effective relationships that lead to the creation of lasting solutions at scale.
We also write and publish on life sciences, health technologies & services, and animal health.
Digitalis Ventures is part of the Digitalis Group which also includes Digitalis Research, an applied research organization building new ideas at the intersection of health and technology, and Digitalis Commons, a non-profit organization developing public-interest technologies for better health.
ABOUT OUR NAME
The Digitalis plant is the natural source of cardioactive steroid glycosides widely used in the treatment of heart disease since the 1700s. Dr. Thomas W. Smith, the father of our founding partner, began his career as a physician-scientist at Harvard by developing a novel radioimmunoassay to enable the safe administration of digitalis. Dr. Smith’s subsequent research program touched on many themes—the health benefits of nature-derived compounds, the importance of measurement science in therapeutic development, rational design in drug discovery, among many others that continue to resonate with our group today. Beyond his research, Dr. Smith was a renowned clinician and beloved mentor to a generation of academic cardiologists. Our name reflects our ongoing commitment to this legacy of both scientific innovation and human connection.
